

Index

a

acquired immunodeficiency syndrome (AIDS) 113
 active pharmaceutical ingredient (API) 38
 Acyl-CoA cholesterol acyltransferase (ACAT) inhibitors 11, 12
 β_2 -adrenergic receptor (β_2 AR) 23
 albumin/creatinine ratio (ACR) 145
 aldosterone 7
 Alimta 157 *see also* pemetrexed
 α -amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) 181
 – competitive receptor antagonists 182
 – HTS assays 183
 – non-competitive receptor antagonists 182
 aminopterin 160
 angiotensin receptor blocker (ARB) 145, 146
 antibody-drug conjugates (ADCs)
 – chemotherapeutic component 213
 – T-DM1, 213 *see also* trastuzumab emtansine (T-DM1)
 antiepileptic drug (AED) 13, 14
 – molecular targets 181
 – perampanel 188
 anti-HIV drugs 113
 antimetabolite theory 159
 antiretroviral drug zidovudine (AZT) 113
 antiretroviral therapy (ART) 121
 anti-therapeutic antibody (ATA) 217, 218
 Apidra[®] 47
 apremilast 6
 – for psoriatic arthritis treatment 6
 aromaticity 170
 – SAR study 184
 artemisinin 30
 aspartate aminotransferase (AST) 222
 AspB28-human insulin 46

avanafil

– adverse reactions 82
 – clinical studies of 81
 – on electroretinogram 79
 – IC₅₀ values of 75
 – in vivo pharmacology 76
 – isoquinoline derivatives, discovery of 65
 – PDE inhibitory profiles 75
 – pyrimidine nucleus structure modification 73
 – scaffold-hopping approaches 67 *see also* scaffold-hopping approaches

b

basal insulin profile 39
 benzimidazoles 16
 benzimidazol-2-one derivatives, binding of 23
 benzothiophene MK2 inhibitor 24, 25
 benzylpyrazolone O-glucosides 94
 biochemical efficiency (BE) 24
 butterfly wing pigment 157

c

captopril 3
 carboxylic acid
 – in monoketo acid motif 117
 C-aryl glucosides 98
 – affinity of 102
 – ring methylation of 103
 C-glucosides
 – disubstituted diarylmethane 104
 – m-diarylmethane 97
 – meta 98
 – ortho 98
 – SAR of 99
 – synthetic route 98

chronic obstructive pulmonary disease (COPD)
 – tiotropium bromide treatment 3
 circulating metabolites 82
 citalopram 10
 cLogP 102, 105
 cobicistat 121
 competitive receptor antagonists of AMPA 182
 continuous subcutaneous insulin infusion (CSII) 48

d

dapagliflozin
 – clinical studies with 108
 – and diet induced obese rats 107
 – discovery of 4
 – identification of 102
 – profiling studies with 105
 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF)
 – antitumor agent 164
 – convergent synthesis 166
 – Lilly's results 163
 – open-chain analog 169
 – resolution of 167
 – SAR results 170
 – structure 167
 – synthesis of 162, 167
 diet induced obese (DIO) rats 106
 – dapagliflozin and 107
 dietary cholesterol absorption, inhibitor of 11
see also ezetimibe
 diketo acid 116
 – bioisosteres of 117
 – enolized/non-enolizable 118
 – metal chelating functions of 122
 diketo acid inhibitors 121
 – HIV-1 integrase and 114
 dipeptidyl peptidase-4 (DPP-4) 129
 – ectodomain 139
 – homodimer structure 139
 – hydrogen bonds 140
 – inhibition of 148
 – inhibitory activity 131
 – rationalization of 139
 drospirenone 7, 8

e

elvitegravir 113
 – discovery of 114
 – monoketo acid integrase inhibitors and 116
 – strand transfer by 120

emtricitabine 123
 endogenous insulin secretion 38
 enzyme-linked immunosorbent assay (ELISA) 217
 epilepsy 183
 erectile dysfunction (ED) 63 *see also* avanafil
 – definition of 63
 – PDE5inhibitor, physicochemical characteristics of 65
 escitalopram 9, 10
 ezetimibe 11, 13

f

fibroblast activating protein (FAP) 142
 first in class medicines
 – approved between 1999-2008 27
 – examples of 27
 first-in-class small-molecule new molecular entities 27, 29
 folate-dependent enzymes 158
 folic acid 160

g

gastrin receptor blockers 15
 gemtuzumab ozogamicin 213, 214
 glomerular filtration rate (GFR) 145
 glucagon-like peptide (GLP)-1 129
 – effects on 148
 glucodynamic profiles 44
 glucose
 – and basal insulin profile, schematic representation of 39
 – regulation by linagliptin 143
 – renal processing of 89
 glucose-dependent insulinotropic peptide (GIP) 129
 glucosuric agents 90
 glycated hemoglobin (HbA1C) 143

h

hemodynamics, avanafil effects on 79
 hepatic enzyme elevations 224
 hepatic impairment
 – linagliptin 150
 hepatitis C virus (HCV) 195
 – clinical development 206
 – HPLC assay 196
 – NS3/4A protease 196
 – peptide truncation study 197
 – *p*-nitroanilide 196
 – pre-clinical development 206
 – protease catalytic domain 197
 – PROVE-3 study 207
 – structure-based inhibitor 200

- substrate-based inhibitor 197, 199
- THIQ 200, 201
- high-fat diet (HFD) 144
- high throughput screening (HTS) 130
 - assay of AMPA 183
 - structures of 130
- HIV-1 integrase
 - and diketo acid inhibitors 114
- HPLC-based assay 196
- Humalog[®] 45 *see also* insulin lispro
- human epidermal growth factor receptor 2 (HER2) 214, 215
- human *ether-à-go-go*-related gene (hERG) channel 135
- human immunodeficiency virus (HIV) 113
- human insulin 39, 40
 - time-dependent, diffusion enabled dissociation of 44
- hydroxybenzamide O-glucosides 90
- hyperglycemia 88
 - effects on 148

i

- imatinib 3
- insulin
 - history of 38
 - protracted glucodynamic profile 44
 - self-association properties 45
 - self-association tendencies of 41
- insulin aspart 46
- insulin degludec 53, 54
- insulin detemir 51, 52
- insulin glargine 50, 51
- insulin glulisine 46
- insulin lispro 46
 - basal utility of 48, 49
 - creation of 45
 - dissociation of 47
 - hexameric complex of 45
 - NPH-like crystal formation 49
- insulin lispro protamine suspension (ILPS) 49
- integrase catalytic reactions 115
- inter-patient variability, Lantus[®] formulation 51
- intra-patient variability, Lantus[®] formulation 50
- in vitro*–*in vivo* extrapolation (IVIVE)
 - perampanel 189
- ionotropic glutamate receptors (iGluRs) 181
- isoquinoline preparation 67

j

- Janus kinase 3 (JAK3) 5

k

- kinase domain receptor (KDR) 68

l

- lamotrigine
 - and BW 288U 14
 - for epilepsy treatment 13
- Lantus[®] formulation
 - time course 50
 - time extension strategy 50
- leucopterin 158
- Levemir[®] formulation 51 *see also* insulin detemir
- linagliptin 129
 - albuminuria-lowering effect of 149
 - bioavailability of 147
 - cardiovascular safety 150
 - clinical pharmacodynamics 148
 - clinical pharmacokinetics 146
 - discovery of 130
 - effects of 145
 - glucose regulation by 143
 - non-linear pharmacokinetics 147
 - outcomes of 150
 - patients with hepatic impairment 150
 - patients with renal impairment 148
 - physicochemical, pharmacological, and kinetic characteristics 141
 - structure of 130
- long-acting insulin analog formulations 48
- losartan 3
- LY231514 172
- LysB28ProB29-human insulin, 45 *see also* insulin lispro

m

- maleimidomethyl-cyclohexane-1-carboxylate (MCC) 215
- maximum tolerated doses (MTDs) 215, 222
- m-diarylmethane C-glucosides 97
- metabotropic glutamate receptors (mGluRs) 181
- methotrexate (MTX) 159, 160
- molecular mechanism of action (MMOA) 19
 - artemisinin 30
 - dose–response relationships 21
 - features of 27
 - IC₅₀ and K_I 22
 - pharmacological action 21
 - safety 22
 - selection of 22
 - target-based drug discovery approach 25

- molecular mechanism of action (MMOA) (*contd.*)
 - therapeutic index 21, 22
 - value and impact of 19
- monoketo acid 118
 - metal chelating functions of 122
- monoketo acid integrase inhibitors
 - and elvitegravir 116
 - structural optimization 119
- multiple daily injections (MDI) therapy 37
- multitargeted antifolate (MTA) 173
- n**
 - Neutral Protamine Hagedorn (NPH)
 - formulation 48, 49
 - neutral protamine lispro (NPL) 49
 - Niemann-Pick C1-like1 (NPC1L1) protein 12
 - nitric oxide (NO)/cGMP signaling pathway 63
 - nitroglycerin (NTG)-induced hypotension, avanafil effects on 80, 81
 - N*-methyl-D-aspartate (NMDA) receptor 30
 - non-competitive receptor antagonists of AMPA 183
 - NS3/4A protease 198
 - activity 195
 - crystal structure of 196
 - structure-based inhibitor 200
 - substrate-based inhibitor 197
 - o**
 - o*-Benzylphenol O-glucosides 95
 - O-glucosides
 - benzylpyrazolone 94
 - hydroxybenzamide 90
 - *o*-benzylphenol 95
 - SGLT SAR
 - – distal substituted diarylmethanes 99
 - – ortho hydroxybenzamides 92
 - – ortho benzylphenols 96
 - SGLT2 inhibitors 89
 - β-O-glucosides
 - susceptibility of 93
 - Oil Red O staining 144
 - omeprazole 15, 16
 - oxadiazinone 184
 - p**
 - pelvic nerve stimulation-induced tumescence 78
 - pemetrexed
 - administration 173
 - discovery of 175
 - origin of 157
 - structural studies 157
 - penile tumescence, potentiation of 76
 - peptide
 - truncation study 197
 - perampanel
 - antiepileptic drug 188
 - *in vitro*–*in vivo* extrapolation 189
 - pharmacokinetic evaluation 189
 - pharmacological evaluation 187
 - phase I 189
 - phase II and III 190
 - PF-3644022 24, 25
 - phenotypic screening 26, 27
 - phenyltriazines 14
 - phlorizin 89
 - phosphodiesterase 4 (PDE4) inhibitors 6
 - phosphodiesterase 5 (PDE5) inhibitors
 - blockade of 63
 - physicochemical characteristics of 65
 - phosphodiesterases (PDEs) 64
 - phthalane derivative 9
 - picoprazole 16
 - piriqualone 182
 - 2-pivaloyl-6-bromo-5-deazapterin 166
 - plasma glucose
 - dose dependent reductions 106, 107
 - p*-nitroanilide (*p*NA) assay 196
 - polymerase approaches 5
 - polynucleotidyl transferases 118
 - polyprotein 195
 - prandial insulin profile 39
 - prandial insulin secretion 48
 - proton-pump inhibitors, 15 *see also*
 - omeprazole
 - pteridine 157
 - pyrazolone O-glucosides 94
 - pyrimethamine 13–15
 - pyrrole 170
 - q**
 - 4-quinolone-3-carboxylic acid 116
 - quinoxalinedione 182
 - r**
 - rapid-acting insulin analogs 41
 - R*-citalopram 10
 - renal function
 - anticipated perturbation on 88
 - SGLT2 transporters in 88
 - renal impairment
 - linagliptin 148
 - renin-angiotensin-aldosterone system (RAAS) 149

retinal function, avanafil effects on 79
ring-break framework modifications 68

s

scaffold-hopping approaches
– monocyclic type A series 68
– monocyclic type B series 68
– ring-break framework modifications 67
– 2-substituted-5-(3,4,5-trimethoxybenzoyl) pyrimidines 70
– 4-substituted-5-(3,4,5-trimethoxybenzoyl) pyrimidines 70
– 5-substituted-5-(3,4,5-trimethoxybenzoyl) pyrimidines 73
SCH 48461 12
S-citalopram 10
scurvy 20
SGLT1 88
SGLT2 potency
– modulation of 101
sildenafil 64
– on electroretinogram 79
– hemodynamic effects 79
– IC₅₀ values of 75
sodium-glucose transporter type 2 (SGLT2) inhibitor
– dapagliflozin 4
– O-glucosides 89
– – benzylpyrazolone 94
– – hydroxybenzamide 90
– – o-benzylphenol 95
– recovery rate 88
– in renal function 88
sofosbuvir 5
Sovaldi[®], 5 *see also* sofosbuvir
spironolactone 7, 8
spirorenone 7, 8
statins 11
Stendra[®], 63 *see also* avanafil
Stribild 123
structure-activity relationship (SAR) 130, 138
– of C-glucosides 99
2-substituted-5-(3,4,5-trimethoxybenzoyl) pyrimidines 70

t

T-1032 65
tadalafil 65
talopram 9, 10

telaprevir
– clinical development 206
– compounds 204
– crystal structure 203
– pre-clinical development 206
– synthesis 205
tenofovir disoproxil fumarate 123
tetrahydrofolate coenzymes 160
tetrasubstituted pyrimidine derivatives 68
tezampanel 182
T↔R transition 41
timoprazole 15, 16
T6 insulin hexamer 42
tiotropium bromide, for COPD treatment 3
tofacitinib 5, 6
T-6932 pyrimidine derivative 69
transforming growth factor β (TGF β) 146
trastuzumab emtansine (T-DM1)
– bioanalysis 216
– chemistry control 218
– clinical pharmacology 220
– manufacturing process 218
– for metastatic breast cancer 4
– molecular design 214
– nonclinical development 219
– parameters 217
– trials and approval 222
Tresiba[®] 53 *see also* insulin degludec
1,3,5-triaryl-1*H*-pyridin-2-one
– discovery of 184
– optimization of 185
trisubstituted pyrimidine derivatives 68
type 1 diabetes mellitus (T1DM), insulin treatment 37
type 2 diabetes mellitus (T2DM) 87
– insulin 87
– treatment 87

u

urinary excretion 108
urine albumin-to-creatinine ratio (UACR) 149

x

xanthin
– uracil substructure of 138
xanthopterin 158
xenograft models 219

